Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1393 • ACR Convergence 2022
Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study
Marie Doyen¹, Marie Perrot², Benoit Ghaye³, Emilie Sapart¹, Deniz Zan³, Aleksandra avramovska¹, Tatiana Sokolova⁴, maria stoenoiu¹, sandra koenig², antoine froidure² and Patrick Durez⁵, ¹Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Pulmonology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Radiology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, ⁵Institute de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium
Background/Purpose: The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. We set up a prospective study to detect ILD, bronchiolitis and nodules in…
Abstract Number: 1409 • ACR Convergence 2022
Impact of a Hybrid Medical Care Model in the Rheumatoid Arthritis Patient-Reported Outcomes: A Non-inferiority Crossover Randomized Study
Guillermo Guaracha Basañez¹, Irazu Contreras-Yáñez², Vivian Estrada-González², Lexli Pacheco-Santiago², Salvador Valverde-Hernández² and Virginia Pascual Ramos³, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirn", Ciudad de México, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico
Background/Purpose: Patients and physicians can naturally adopt hybrid healthcare models (HC), that combine face-to-face consultations (FFC) with telemedicine. The study's objective was to compare the…
Abstract Number: 1428 • ACR Convergence 2022
Molecular and Clinical Profiling of Rheumatoid Arthritis Patients Predicts the Response to Rituximab
Daniel Toro-Domínguez¹, José Linares-Blanco¹, Raúl López-Domínguez², Pilar S. López-Garrido², Georgina Galicia-Rosas¹, Pedro Carmona-Sáez² and Marta Alarcon-Riquelme¹, ¹Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²University of Granada, Granada, Spain
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent rheumatic diseases, mainly characterized by chronically painful, swollen joints that can severely impair physical function…
Abstract Number: 1603 • ACR Convergence 2022
Intervention with Methotrexate in Arthralgia at Risk for Rheumatoid Arthritis to Reduce the Development of Persistent Arthritis and Its Disease Burden (TREAT EARLIER): A Double-blind, Randomized, Placebo-controlled Trial
Doortje Krijbolder¹, Marloes Verstappen¹, Bastiaan van Dijk², Yousra Dakkak¹, Aleid Boer¹, Yune-Jung Park¹, Marianne E. de Witt-Luth³, Karen Visser⁴, Marc Kok⁵, Esmeralda T.H. Molenaar⁶, Pascal de Jong⁷, Stephan Böhringer⁸, Tom Huizinga¹, CF Allaart¹, Ellis Niemantsverdriet⁹ and Annette van der Helm-van Mil¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre (LUMC), Leiden, Netherlands, ³Reinier de Graaf Ziekenhuis, Delft, Netherlands, ⁴Haga Ziekenhuis, Amsterdam, Netherlands, ⁵Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Groene Hart Ziekenhuis, Gouda, Netherlands, ⁷ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁸Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, ⁹LUMC, Leiden, Netherlands, ¹⁰Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and requires long term treatment to suppress inflammation. Currently, treatment is started when arthritis is…
Abstract Number: 1680 • ACR Convergence 2022
Module Signatures of Synovial Single-cell States Identify Disease Phenotypes in Early Treatment-naive Rheumatoid Arthritis
Felice Rivellese¹, Elena Pontarini², Cankut Cubuk¹, Alessandra Nerviani¹, Liliane Fossati-Jimack¹, Anna Surace¹, Elisabetta Sciacca³, Katriona Goldmann¹, Michele Bombardieri⁴, Myles Lewis¹ and Costantino Pitzalis¹, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Queen Mary University of London, Biancavilla, Italy, ⁴Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom
Background/Purpose: Despite extensive studies, the relationship between circulating and local immune cells and clinico-pathological features of Immune-Mediated Inflammatory Diseases remains unclear. Recently, synovium-specific cell states…
Abstract Number: 1755 • ACR Convergence 2022
Improving Quality of Life Through Connection: A Scoping Review of Peer Coaching Interventions in the Field of Rheumatology
Megan Creasman¹, Mackenzie Brown², Yuliana Domínguez Páez³, Michelle Demetres⁴, Monika Safford⁴ and Iris Navarro-Millan⁴, ¹NYP-Weill Cornell, New York, NY, ²Weill Cornell Medicine, Brooklyn, NY, ³Weill Cornell Medicine, Bronx, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Peer coaches are lay individuals providing health education and behavior change interventions, and often have the same condition as the person that they are…
Abstract Number: 1952 • ACR Convergence 2022
Burden of Disease in Refractory Rheumatoid Arthritis
Kristin Wipfler¹, Bobby Kwanghoon Han², Urbano Sbarigia³, Federico Zazzetti⁴, Anna Sheahan⁵, Iris Lin⁶, Patricia Katz⁷, Evo Alemao⁸ and Kaleb Michaud⁹, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²Division of Rheumatology, University of Washington, Seattle, WA, ³Johnson & Johnson, Beerse, Belgium, ⁴Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁵Janssen Research and Development, Chapel Hill, NC, ⁶Janssen, Horsham, PA, ⁷UCSF, San Rafael, CA, ⁸Janssen, Princeton, NJ, ⁹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment and the improved outcomes that have been associated with the expanding number of advanced therapies available, a substantial…
Abstract Number: 1968 • ACR Convergence 2022
Dysregulation of γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Olga Kryštůfková², Nora Petrovská², Petra Hánová¹, Hana Hulejová¹, Jiří Vencovský², Ladislav Šenolt² and Mária Filková², ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Non-conventional T cells (γδ-T and NK-T cells) and natural killer (NK) cells are involved in the regulation of the immune system, and their alteration…
Abstract Number: 1986 • ACR Convergence 2022
Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen Are Less Likely to Respond to Anti-IL6R Treatment
Sofie Falkenløve Madsen¹, Dovile Sinkeviciute², Christian Thudium², Morten Karsdal² and Anne-Christine Bay-Jensen², ¹University of Copenhagen / Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, autoimmune disease, which normally is characterized by inflammation and thickening of the synovial membrane leading to swollen and…
Abstract Number: 2003 • ACR Convergence 2022
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
Malin Erlandsson¹, Karin Andersson¹, Sofia Töyrä Silfverswärd², Rille pullerits² and Maria Bokarewa², ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Combination of IFN-stimulated genes known as IFN signature, helps to predict disease activity and treatment response in several autoimmune diseases, including rheumatoid arthritis (RA).…
Abstract Number: 2180 • ACR Convergence 2022
Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner
Akilan Krishnamurthy¹, Jitong Sun², Alexandra Circiumaru¹, Yogan Kisten¹, Koji Sakuraba³, Thuy Tran¹, Peter Damberg¹, Patrik Jarvoll¹, Li Lu¹, Katalin Sándor¹, Tunhe Zhou⁴, vivianne malmström¹, Camilla I. Svensson¹, Aase Hensvold¹, Anca Catrina¹, Lars Klareskog¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Solna, Sweden, ³Karolinska Institutet and Karolinska University Hospital, Fukuoka, Japan, ⁴Stockholm University, Stockholm, Sweden
Background/Purpose: The appearance of anti-citrullinated protein antibodies (ACPAs) in the circulation represents a major risk factor for developing rheumatoid arthritis (RA). Here we studied whether…
Abstract Number: 2248 • ACR Convergence 2022
Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort
Gregory McDermott¹, Keigo Hayashi², Kazuki Yoshida¹, Matthew Moll¹, Michael Cho¹, Tracy Doyle¹, Paul Dellaripa¹, Rachel Putman¹, Raul San Jose Estepar¹, George Washko¹, Elizabeth Regan³, Hiroto Hatabu¹, Gary M Hunninghake¹, Edwin Silverman¹ and Jeffrey Sparks⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³National Jewish Health, Denver, CO, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Subpleural interstitial lung abnormalities (ILA) may be a form of subclinical or preclinical interstitial lung disease (ILD) and have been reported in up to…
Abstract Number: 0055 • ACR Convergence 2022
Protective Role for Mast Cells in TNF-induced Inflammatory-Erosive Arthritis and Its Associated Lymphatic Dysfunction in Mice
Yue Peng¹, H. Mark Kenney², Karen Bentley³, Lianping Xing⁴, Christopher Ritchlin⁵ and Edward Schwarz¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Henrietta, NY, ³University of Rochester, Rochester, ⁴University of Rochester Medical Center, Webster, NY, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1). Mast cells (MCs) regulate lymphatic vessels by releasing inflammatory and vasoactive mediators (e.g. histamine) (2). Previous…
Abstract Number: 0113 • ACR Convergence 2022
Escalation to Biologics After Methotrexate Among US Veterans with Rheumatoid Arthritis Living in Rural versus Urban Areas
Anisha Naik¹, Katherine Wysham², Bryant England³, Punyasha Roul⁴, Michael George⁵, Joshua Baker⁵, Jennifer Barton⁶, Jean Liew⁷, Una Makris⁸, Gail Kerr⁹, Grant Cannon¹⁰, Ted Mikuls¹¹ and Namrata Singh¹², ¹VA Puget Sound, Seattle, WA, ²VA Puget Sound/University of Washington, Seattle, WA, ³University of Nebraska Medical Center, Omaha, NE, ⁴UNMC, Omaha, NE, ⁵University of Pennsylvania, Philadelphia, PA, ⁶VA Portland Health Care System/OHSU, Portland, OR, ⁷Boston University, Boston, MA, ⁸UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Retired, Salt Lake City, UT, ¹¹Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ¹²University of Washington, Bellevue, WA
Background/Purpose: Timely diagnosis and initiation of appropriate treatments are imperative to improve outcomes for patients with rheumatoid arthritis (RA). Racial and ethnic disparities in RA…
Abstract Number: 0231 • ACR Convergence 2022
Primary Care Physician’s Perspective and Needs on Early Rheumatoid Arthritis Diagnosis: REUCARE Program for Early Referral
Camille Bourgeois¹, Jorge Olmedo Galindo², Juan Molina¹, Gema Fernandez-Plana², Julia Martinez-Barrio¹, Javier Rivera³ and Isabel Castrejon⁴, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Gerencia Asistencial Atención Primaria, Comunidad de Madrid, Madrid, Spain, ³Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁴Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Primary care physicians (PCPs) play a crucial role in early recognition and rapid referral of patients with inflammatory arthritis to improve early management and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].